Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 8/2018

Open Access 01-10-2018 | Review Article

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications

Authors: Rudolf A. Werner, Ralph A. Bundschuh, Lena Bundschuh, Mehrbod S. Javadi, Takahiro Higuchi, Alexander Weich, Sara Sheikhbahaei, Kenneth J. Pienta, Andreas K. Buck, Martin G. Pomper, Michael A. Gorin, Constantin Lapa, Steven P. Rowe

Published in: Annals of Nuclear Medicine | Issue 8/2018

Login to get access

Abstract

Both prostate-specific membrane antigen (PSMA)- and somatostatin receptor (SSTR)-targeted positron emission tomography (PET)-based imaging agents for prostate carcinoma and neuroendocrine tumors, respectively, are seeing rapidly expanding use. In addition to diagnostic applications, both classes of radiotracers can be used to triage patients for theranostic endoradiotherapy. While interpreting PSMA- or SSTR-targeted PET/computed tomography (CT) scans, the reader has to be aware of certain pitfalls. Adding to the complexity of the interpretation of those imaging agents, both normal biodistribution, and also false-positive and -negative findings differ between PSMA- and SSTR-targeted PET radiotracers. Herein summarized under the umbrella term molecular imaging reporting and data systems (MI-RADS), two novel RADS classifications for PSMA- and SSTR-targeted PET imaging are described (PSMA- and SSTR-RADS). Notably, PSMA- and SSTR-RADS are structured in a reciprocal fashion, i.e., if the reader is familiar with one system, the other system can readily be applied, as well. In the present review, we will discuss the most common pitfalls on PSMA- and SSTR-targeted PET/CT, briefly introduce PSMA- and SSTR-RADS, and define a potential future role of the umbrella framework MI-RADS compared to other classification systems.
Literature
1.
Kulkarni HR, Baum RP. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy. PET Clin. 2014;9(1):91–7.CrossRefPubMed
2.
Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K. 68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs. Ann Nucl Med. 2015;29(1):1–7.CrossRefPubMed
3.
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German Multicenter Study Investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90.CrossRefPubMed
4.
Werner RA, Weich A, Higuchi T, Schmid JS, Schirbel A, Lassmann M, et al. Imaging of chemokine receptor 4 expression in neuroendocrine tumors—a triple tracer comparative approach. Theranostics. 2017;7(6):1489–98.CrossRefPubMedPubMedCentral
5.
Rowe SP, Gorin MA, Pomper MG. Imaging of prostate-specific membrane antigen using [(18)F]DCFPyL. PET Clin. 2017;12(3):289–96.CrossRefPubMed
6.
Werner RA, Andree C, Javadi MS, Lapa C, Buck AK, Higuchi T, et al. A voice from the past: rediscovering the Virchow node with prostate-specific membrane antigen-targeted (18)F-DCFPyL positron emission tomography imaging. Urology. 2018;117:18–21.CrossRefPubMed
7.
Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of [(18)F]PSMA-1007 PET/CT in 251 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2018.
8.
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. Evaluation of hybrid. J Nucl Med. 2015;56(5):668–74.CrossRefPubMed
9.
Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, et al. Safety, biodistribution, and radiation dosimetry of (68)Ga-OPS202 in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase I imaging study. J Nucl Med. 2018;59(6):909–14.CrossRefPubMed
10.
Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117–36.CrossRefPubMed
11.
Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68 Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500–16.CrossRefPubMed
12.
Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59(3):469–78.CrossRefPubMed
13.
Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, et al. Development of standardized image interpretation for 68 Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. 2017;44(10):1622–35.CrossRefPubMed
14.
Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7(5):1149–58.CrossRefPubMedPubMedCentral
15.
Tessler FN, Middleton WD, Grant EG. Thyroid imaging reporting and data system (TI-RADS): a user’s guide. Radiology 2018;287(1):29–36.CrossRefPubMed
16.
Orel SG, Kay N, Reynolds C, Sullivan DC. BI-RADS categorization as a predictor of malignancy. Radiology 1999;211(3):845–50.CrossRefPubMed
17.
Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 status update and future directions. Eur Urol. 2018.
18.
Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies. Eur Urol. 2018;73(4):485–7.CrossRefPubMed
19.
Rowe SP, Pienta KJ, Pomper MG, Gorin MA. Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J Nucl Med. 2018;59(3):479–85.CrossRefPubMedPubMedCentral
20.
Werner RA, Solnes LB, Javadi MS, Weich A, Gorin MA, Pienta KJ, et al. SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: a proposed standardization framework. J Nucl Med. 2018;59(7):1085–91.CrossRefPubMed
21.
Barinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19(6):856–70.CrossRefPubMedPubMedCentral
22.
Werner RA, Sheikhbahaei S, Jones KM, Javadi MS, Solnes LB, Ross AE, et al. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia. Ann Nucl Med. 2017;31(9):696–702.CrossRefPubMedPubMedCentral
23.
Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, et al. (68)Ga-PSMA-HBED-CC uptake in cervical, coeliac and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nucl Med. 2018.
24.
Hermann RM, Djannatian M, Czech N, Nitsche M. Prostate-specific membrane antigen PET/CT: false-positive results due to sarcoidosis? Case Rep Oncol. 2016;9(2):457–63.CrossRefPubMedPubMedCentral
25.
Ardies PJ, Gykiere P, Goethals L, De Mey J, De Geeter F, Everaert H. PSMA uptake in mediastinal sarcoidosis. Clin Nucl Med. 2017;42(4):303–5.CrossRefPubMed
26.
Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W. Biodistribution of [(68)Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol Imaging Biol. 2016;18(3):428–36.CrossRefPubMed
27.
Pyka T, Weirich G, Einspieler I, Maurer T, Theisen J, Hatzichristodoulou G, et al. 68 Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med. 2016;57(3):367–71.CrossRefPubMed
28.
De Coster L, Sciot R, Everaerts W, Gheysens O, Verscuren R, Deroose CM, et al. Fibrous dysplasia mimicking bone metastasis on (68)GA-PSMA PET/MRI. Eur J Nucl Med Mol Imaging 2017;44(9):1607–8.CrossRefPubMed
29.
Vamadevan S, Le K, Bui C, Mansberg R. Incidental PSMA uptake in an undisplaced fracture of a vertebral body. Clin Nucl Med. 2017;42(6):465–6.CrossRefPubMed
30.
Rowe SP, Deville C, Paller C, Cho SY, Fishman EK, Pomper MG, et al. Uptake of (18)F-DCFPyL in Paget’s disease of bone, an important potential pitfall in clinical interpretation of PSMA PET studies. Tomography. 2015;1(2):81–4.CrossRefPubMedPubMedCentral
31.
Rischpler C, Maurer T, Schwaiger M, Eiber M. Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nucl Med Mol Imaging 2016;43(1):193–4.CrossRefPubMed
32.
Vamadevan S, Le K, Shen L, Ha L, Mansberg R. Incidental prostate-specific membrane antigen uptake in a peripheral nerve sheath tumor. Clin Nucl Med. 2017;42(7):560–2.CrossRefPubMed
33.
Jain TK, Jois AG, Kumar VS, Singh SK, Kumar R, Mittal BR. Incidental detection of tracer avidity in meningioma in (68)Ga-PSMA PET/CT during initial staging for prostate cancer. Rev Esp Med Nucl Imagen Mol. 2017;36(2):133–4.PubMed
34.
Bhardwaj H, Stephens M, Bhatt M, Thomas PA. Prostate-specific membrane antigen PET/CT findings for hepatic hemangioma. Clin Nucl Med. 2016;41(12):968–9.CrossRefPubMed
35.
Kanthan GL, Hsiao E, Kneebone A, Eade T, Schembri GP. Desmoid tumor showing intense uptake on 68 Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016;41(6):508–9.CrossRefPubMed
36.
Zacho HD, Nielsen JB, Dettmann K, Hjulskov SH, Petersen LJ. 68 Ga-PSMA PET/CT uptake in intramuscular myxoma imitates prostate cancer metastasis. Clin Nucl Med. 2017;42(6):487–8.CrossRefPubMed
37.
Malik D, Basher RK, Mittal BR, Jain TK, Bal A, Singh SK. 68 Ga-PSMA expression in pseudoangiomatous stromal hyperplasia of the breast. Clin Nucl Med. 2017;42(1):58–60.CrossRefPubMed
38.
Taywade SK, Damle NA, Bal C. PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer? Clin Nucl Med. 2016;41(5):e263-5.CrossRefPubMed
39.
Lutje S, Gomez B, Cohnen J, Umutlu L, Gotthardt M, Poeppel TD, et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68 Ga-HBED-CC-PSMA PET/CT. Clin Nucl Med. 2017;42(1):20–5.CrossRefPubMed
40.
Derlin T, Kreipe HH, Schumacher U, Soudah B. PSMA expression in tumor neovasculature endothelial cells of follicular thyroid adenoma as identified by molecular imaging using 68 Ga-PSMA ligand PET/CT. Clin Nucl Med. 2017;42(3):e173-e4.CrossRef
41.
Rowe SP, Gorin MA, Hammers HJ, Pomper MG, Allaf ME, Javadi MS. Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. Clin Nucl Med. 2016;41(1):83–5.CrossRefPubMedPubMedCentral
42.
Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET/CT. Ann Nucl Med. 2015;29(10):877–82.CrossRefPubMedPubMedCentral
43.
Vamadevan S, Shetty D, Le K, Bui C, Mansberg R, Loh H. Prostate-specific membrane antigen (PSMA) avid pancreatic neuroendocrine tumor. Clin Nucl Med. 2016;41(10):804–6.CrossRefPubMed
44.
Jacobsson H, Larsson P, Jonsson C, Jussing E, Gryback P. Normal uptake of 68 Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET. Clin Nucl Med. 2012;37(4):362–5.CrossRefPubMed
45.
Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012;14(74):71–81.PubMed
46.
Mohandas JT, Ravi Kumar AS, Ranganathan D, Healy H, Huang YT, O’Loughlin B, et al. Splenunculus masquerading as a neuroendocrine tumor of the pancreatic allograft in a kidney-pancreas recipient. Transplantation. 2013;96(8):e59–62.CrossRefPubMed
47.
Li X, Samnick S, Lapa C, Israel I, Buck AK, Kreissl MC, et al. 68 Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors. EJNMMI Res. 2012;2(1):52.CrossRefPubMedPubMedCentral
48.
Lapa C, Reiter T, Kircher M, Schirbel A, Werner RA, Pelzer T, et al. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. Oncotarget. 2016;7(47):77807–14.CrossRefPubMedPubMedCentral
49.
Schatka I, Wollenweber T, Haense C, Brunz F, Gratz KF, Bengel FM. Peptide receptor-targeted radionuclide therapy alters inflammation in atherosclerotic plaques. J Am Coll Cardiol. 2013;62(24):2344–5.CrossRefPubMed
50.
Brogsitter C, Hofmockel T, Kotzerke J. (68)Ga DOTATATE uptake in vertebral hemangioma. Clin Nucl Med. 2014;39(5):462–3.CrossRefPubMed
51.
Yamaga LYI, Cunha ML, Campos Neto GC, Garcia MRT, Yang JH, Camacho CP, et al. (68)Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging. 2017;44(10):1695–701.CrossRefPubMed
52.
Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, Hicks RJ, et al. (68)Ga-DOTATATE and (18)F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 2016;16(1):22.CrossRefPubMedPubMedCentral
53.
Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD, Knowledge N. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153-63.PubMed
54.
Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro Oncol. 2016;18(7):1021–7.CrossRefPubMedPubMedCentral
55.
Lapa C, Lohr M, Bluemel C, Monoranu CM, Herrmann K. Primary central nervous system lymphoma and meningioma in DOTATATE PET/CT. Clin Nucl Med. 2013;38(12):994–5.CrossRefPubMed
56.
Elgeti F, Amthauer H, Denecke T, Steffen I, Heuck F, Stelter L, et al. Incidental detection of breast cancer by 68 Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours. Nuklearmedizin 2008;47(6):261–5.PubMed
57.
Nockel P, Millo C, Keutgen X, Klubo-Gwiezdzinska J, Shell J, Patel D, et al. The rate and clinical significance of incidental thyroid uptake as detected by Gallium-68 DOTATATE positron emission tomography/computed tomography. Thyroid 2016;26(6):831–5.CrossRefPubMedPubMedCentral
58.
Yamaga LYI, Wagner J, Funari MBG. 68 Ga-DOTATATE PET/CT in nonneuroendocrine tumors: a pictorial essay. Clin Nucl Med. 2017;42(6):e313–e16.CrossRefPubMed
59.
Werner RA, Ilhan H, Lehner S, Papp L, Zsoter N, Schatka I, et al. Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2018.
60.
Lapa C, Werner RA, Herrmann K. Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography. Endocrine 2016;51(3):556–7.CrossRefPubMed
61.
Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800–16.CrossRefPubMedPubMedCentral
62.
Muller SP, Ezziddin S, Antoch G, Lauenstein T, Amthauer H, Haug AR, et al. Selective intraarterial radiotherapy (SIRT) of malignant liver tumors. Nuklearmedizin 2017;56(5):162–70.CrossRefPubMed
63.
Barbier CE, Garske-Roman U, Sandstrom M, Nyman R, Granberg D. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2016;43(8):1425–31.CrossRefPubMed
64.
Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, et al. (68)Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med. 2017;58(10):1617–23.CrossRefPubMed
65.
Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, et al. 68 Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessment: results of a prospective study on 50 patients. J Nucl Med. 2017;58(2):307–11.CrossRefPubMedPubMedCentral
66.
67.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.CrossRefPubMedPubMedCentral
68.
Buck AK, Stolzenburg A, Hanscheid H, Schirbel A, Luckerath K, Schottelius M, et al. Chemokine receptor—directed imaging and therapy. Methods. 2017;130:63–71.CrossRefPubMed
69.
Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018.
70.
Reynolds TS, Bandari RP, Jiang Z, Smith CJ. Lutetium-177 labeled bombesin peptides for radionuclide therapy. Curr Radiopharm. 2016;9(1):33–43.CrossRefPubMed
71.
Reiter T, Werner RA, Bauer WR, Lapa C. Detection of cardiac sarcoidosis by macrophage-directed somatostatin receptor 2-based positron emission tomography/computed tomography. Eur Heart J. 2015;36(35):2404.CrossRefPubMed
Metadata
Title
Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications
Authors
Rudolf A. Werner
Ralph A. Bundschuh
Lena Bundschuh
Mehrbod S. Javadi
Takahiro Higuchi
Alexander Weich
Sara Sheikhbahaei
Kenneth J. Pienta
Andreas K. Buck
Martin G. Pomper
Michael A. Gorin
Constantin Lapa
Steven P. Rowe
Publication date
01-10-2018
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 8/2018
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-018-1291-7

Other articles of this Issue 8/2018

Annals of Nuclear Medicine 8/2018 Go to the issue

Original Article

Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma

Original Article

Detectability of residual invasive bladder cancer in delayed 18F-FDG PET imaging with oral hydration using 500 mL of water and voiding-refilling

Original Article

Prognostic value of 68 Ga PSMA I&T PET/CT SUV parameters on survival outcome in advanced prostat cancer

Invited Review Article

CXCR4-directed theranostics in oncology and inflammation

Short Communication

Diagnosing polymyalgia rheumatica on 18F-FDG PET/CT: typical uptake patterns

Original Article

Reproducibility of standardized uptake values of same-day randomized 68Ga-PSMA-11 PET/CT and PET/MR scans in recurrent prostate cancer patients